Mohammad Jafari, Leila Omidvar, Aliyar Pirouzi, Saeed Jahandideh, Nader Bagheri, Zahra Amirkhani, Atefeh Alipour, Abbas Salmani, Ali Zarrabi, Meghdad Abdollahpour-Alitappeh, Hosein Shahsavarani
{"title":"一种新型鼻内纳米佐剂百日咳疫苗，在啮齿动物模型中具有增强的粘膜递送和免疫原性。","authors":"Mohammad Jafari, Leila Omidvar, Aliyar Pirouzi, Saeed Jahandideh, Nader Bagheri, Zahra Amirkhani, Atefeh Alipour, Abbas Salmani, Ali Zarrabi, Meghdad Abdollahpour-Alitappeh, Hosein Shahsavarani","doi":"10.7883/yoken.JJID.2024.292","DOIUrl":null,"url":null,"abstract":"<p><p>The present study developed a novel nano-structured nasal Bordetella pertussis vaccine candidate using encapsulating filamentous haemagglutinin (FHA) and pertussis toxoid (PTd) into N-trimethyl chitosan (TMC) with the help of CpG as an adjuvant and crosslinker (CpG-adjuvanted TMC/PTd-FHA), followed by physicochemical characterization and immune response evaluation after nasal administration. The TMC/CpG/PTd-FHA nanoparticle (NP) exhibited a particle size and zeta potential of 289.4 nm and +25.7 mV, respectively. The antigen/toxoid-loaded NPs exhibited >80% efficacy for encapsulation into polymer matrices, whereas in vitro antigen/toxoid release was found to be 95.18% after 96 hours. High immunization rates were observed in NP-treated mice with increased IgG and secretory IgA levels and proper capability to induce IFN-γ, IL-4, and IL-17 compared with the control group. Overall, nasal administration of the proposed approach, utilizing CpG as an adjuvant and crosslinker, could elicit humoral and Th1-type cellular immune responses, demonstrating promising potential as a vaccine delivery system.</p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A novel intranasal nano-adjuvanted pertussis vaccine with enhanced mucosal delivery and immunogenicity in a rodent model.\",\"authors\":\"Mohammad Jafari, Leila Omidvar, Aliyar Pirouzi, Saeed Jahandideh, Nader Bagheri, Zahra Amirkhani, Atefeh Alipour, Abbas Salmani, Ali Zarrabi, Meghdad Abdollahpour-Alitappeh, Hosein Shahsavarani\",\"doi\":\"10.7883/yoken.JJID.2024.292\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The present study developed a novel nano-structured nasal Bordetella pertussis vaccine candidate using encapsulating filamentous haemagglutinin (FHA) and pertussis toxoid (PTd) into N-trimethyl chitosan (TMC) with the help of CpG as an adjuvant and crosslinker (CpG-adjuvanted TMC/PTd-FHA), followed by physicochemical characterization and immune response evaluation after nasal administration. The TMC/CpG/PTd-FHA nanoparticle (NP) exhibited a particle size and zeta potential of 289.4 nm and +25.7 mV, respectively. The antigen/toxoid-loaded NPs exhibited >80% efficacy for encapsulation into polymer matrices, whereas in vitro antigen/toxoid release was found to be 95.18% after 96 hours. High immunization rates were observed in NP-treated mice with increased IgG and secretory IgA levels and proper capability to induce IFN-γ, IL-4, and IL-17 compared with the control group. Overall, nasal administration of the proposed approach, utilizing CpG as an adjuvant and crosslinker, could elicit humoral and Th1-type cellular immune responses, demonstrating promising potential as a vaccine delivery system.</p>\",\"PeriodicalId\":14608,\"journal\":{\"name\":\"Japanese journal of infectious diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese journal of infectious diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.7883/yoken.JJID.2024.292\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese journal of infectious diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7883/yoken.JJID.2024.292","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
A novel intranasal nano-adjuvanted pertussis vaccine with enhanced mucosal delivery and immunogenicity in a rodent model.
The present study developed a novel nano-structured nasal Bordetella pertussis vaccine candidate using encapsulating filamentous haemagglutinin (FHA) and pertussis toxoid (PTd) into N-trimethyl chitosan (TMC) with the help of CpG as an adjuvant and crosslinker (CpG-adjuvanted TMC/PTd-FHA), followed by physicochemical characterization and immune response evaluation after nasal administration. The TMC/CpG/PTd-FHA nanoparticle (NP) exhibited a particle size and zeta potential of 289.4 nm and +25.7 mV, respectively. The antigen/toxoid-loaded NPs exhibited >80% efficacy for encapsulation into polymer matrices, whereas in vitro antigen/toxoid release was found to be 95.18% after 96 hours. High immunization rates were observed in NP-treated mice with increased IgG and secretory IgA levels and proper capability to induce IFN-γ, IL-4, and IL-17 compared with the control group. Overall, nasal administration of the proposed approach, utilizing CpG as an adjuvant and crosslinker, could elicit humoral and Th1-type cellular immune responses, demonstrating promising potential as a vaccine delivery system.
期刊介绍：
Japanese Journal of Infectious Diseases (JJID), an official bimonthly publication of National Institute of Infectious Diseases, Japan, publishes papers dealing with basic research on infectious diseases relevant to humans in the fields of bacteriology, virology, mycology, parasitology, medical entomology, vaccinology, and toxinology. Pathology, immunology, biochemistry, and blood safety related to microbial pathogens are among the fields covered. Sections include: original papers, short communications, epidemiological reports, methods, laboratory and epidemiology communications, letters to the editor, and reviews.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
